AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01936324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, 7.5%
Description: Gel containing Olumacostat Glasaretil
Study NCT01936324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, Vehicle
Description: Vehicle (placebo) gel
Study NCT03171532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strands of Hamstring Autograft in ACL reconstruction
Description: The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
Study NCT02344017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-204
Description: co-administered with prednisone, orally daily
Study NCT02344017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: ODM-204 is co-administered with oral prednisone
Study NCT00195884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise
Description: Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
Study NCT03728959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal (Nutridrink)
Description: Liquid meal ingested over 1 minute.
Study NCT03728959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Description: Subcutaneous injected GIP
Study NCT03728959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: Subcutaneous injected GLP-2
Study NCT03728959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Subcutaneous injected Placebo (saline)
Study NCT04008056 — intervention group
Intervention type: OTHER
Intervention: Patient Reported Outcome questionnaire
Description: 34 question form to assess patient symptoms
Study NCT00771095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: podcasting
Study NCT00771095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: podcasting
Study NCT03018223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Myeloablative conditioning: 40 mg/m\^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m\^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
Study NCT03018223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol\*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol\*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
Study NCT03018223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
Study NCT03018223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: Reduced intensity conditioning: 200 centigray (cGy) on day -1.
Study NCT03018223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Hematopoietic Cell Transplantation (HCT)
Description: On day 0, patients will receive a peripheral blood hematopoietic cell graft.
Study NCT03018223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR)
Description: GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
Study NCT03018223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
Study NCT03018223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is > 1,000/mm\^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
Study NCT00805597 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
Study NCT00805597 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: no radiation
Description: no radiotherapy
Study NCT01058525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: median nerve block
Description: median nerve block performed using ultrasound guidance
Study NCT01058525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: median nerve block after hydro-dissection
Description: median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
Study NCT03801187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study NCT03801187 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study NCT03801187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study NCT03801187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Er.YAg laser treatment will be provided on the implant surface.
Study NCT03801187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Powder
Description: An air powder device will be treatment will be provided on the implant surface.
Study NCT03507153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bre-flex maxillary partial denture
Description: Partial denture fabricated from Bre.flex material.
Study NCT03507153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEK maxillary partial denture
Description: Partial denture fabricated from PEEK material.
Study NCT02457442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Remifentanil
Description: High propofol and low remifentanil, changing remifentanil (up-and-down method)
Study NCT02457442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Remifentanil
Description: Low propofol and high remifentanil, changing propofol (up-and-down method)
Study NCT02457442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and Remifentanil
Description: High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
Study NCT02457442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and Remifentanil
Description: Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
Study NCT02457442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPR 1
Description: Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision.
Study NCT02457442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPR2
Description: Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision.
Study NCT02803671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TFU-NIRS
Study NCT02803671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Study NCT02803671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Study NCT00477464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250mg once daily
Study NCT00477464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 2000mg/m\^2 twice daily (14 days out of 21 days)
Study NCT03532269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nightly App
Description: The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
Study NCT00489645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo SC during euglycemia
Study NCT00489645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide
Description: pramlintide SC during eglycemia
Study NCT00489645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo during hyperglycemia
Study NCT00489645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide
Description: pramlintide SC during hyperglycemia
Study NCT00863798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release 10mg
Description: 10 mg tablet, once daily dosing for 8 weeks
Study NCT00863798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release 50 mg
Description: 50 mg tablet, once daily dosing for 8 weeks
Study NCT00863798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Study NCT03298529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose solution
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%
Study NCT03298529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional egg pasta
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
Study NCT03298529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasta with eight egg whites/kg flour
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
Study NCT03298529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasta with four eggs/kg flour
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
Study NCT03298529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperproteic pasta (with added gluten and albumin)
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
Study NCT03298529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasta with only four egg whites/kg flour
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
Study NCT02142634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide granules 9 mg
Description: per day
Study NCT02142634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granules
Description: per day
Study NCT04296422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs or oral contraceptives treatment
Description: Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
Study NCT04296422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dose acupuncture
Description: Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
Study NCT04296422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose acupuncture
Description: Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner
Study NCT00980577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NUUS
Description: Sonosite Micro Maxx
Study NCT03049098 — intervention group
Intervention type: BEHAVIORAL
Intervention: Simulation
Description: A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing
Study NCT03932578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate
Description: Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
Study NCT03932578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Patients will receive IV metoclopramide 10 mg in 2 ml
Study NCT03916822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Alloantigen-specific B-cells
Description: Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
Study NCT01982786 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image guided external beam radiotherapy with or without brachytherapy boost
Description: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
Study NCT01982786 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy boost
Study NCT02509312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
Study NCT02509312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
Study NCT04492137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cannulation technique
Description: Participants in the ultra early NKF group will be submitted to 2 standard cannulation attempts (2 contacts with the papilla) before starting NKF. If any of these 2 attemps is successful, NKF won't take place. If NKF is indeed performed and cannulation is not achieved within 8 minutes, the endoscopist is free to perform techniques other than NKF. On the other hand, participants in the standard cannulation group in which cannulation is not achieved within 8 minutes can cross-over to other advanced cannulation techniques (e.g. NKF). For ethical reasons we choose to exclude flat and intradiverticular/diverticular border papillas.~During ERCP all participants will be submitted to PEP prophylaxis with rectal indomethacin. A pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct.~For the purposes of the study, a dedicated form (attached) will be created with the various variables to be analyzed
Study NCT02646735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Description: Fulvestrant 500mg will be given monthly.
Study NCT02646735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane 25 mg
Description: Exemestane 25mg will be given once daily.
Study NCT03046797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroptic intubation through Boussignac valve opening
Description: After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
Study NCT03046797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Fibroptic intubation
Description: After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
Study NCT02356796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group treatment
Description: Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months.
Study NCT02356796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy treatment
Description: Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
Study NCT02675803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 treatment
Study NCT02675803 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VAY736 placebo
Description: VAY736 placebo
Study NCT04735913 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone acetate tablets
Description: Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
Study NCT04735913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets
Description: Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
Study NCT03954223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low sugar and carbohydrate diet
Description: Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)
Study NCT03954223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Limited Eating
Description: 16-hour fast/8-hour feed for 3 days per week
Study NCT03954223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: CGM (used to monitor adherence and glycemic outcomes without real time feedback)
Study NCT04476836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy
Description: Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
Study NCT02483845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab